Available Technologies

ADDITIONAL FILTERS

292 available technologies

FEATURED TECHNOLOGY

Near-Infrared Dye with Large Stokes Shift for Simultaneous Multichannel in vivo Molecular Imaging

Fluorescent labels having near-infrared (NIR) emission wavelengths have the ability to penetrate tissue deeper than other emission wavelengths, providing enormous potential for non-invasive imaging applications. However, advancement of optical imaging (particularly NIR imaging) is hindered by the limitation of narrow Stokes shift of most infrared dyes currently available in the market. Vanderbilt researchers have developed a novel NIR dye (4-Sulfonir) for multichannel imaging that enables in vivo imaging of multiple targets due to its large Stokes shift. 4-Sulfonir with its unique large Stokes shift (~150 nm) and wide excitation spectrum could be used in parallel with other NIR dyes for imaging two molecular events simultaneously in one target.
FEATURED TECHNOLOGY

Novel Target Regulating Angiogenesis

Vanderbilt scientists have discovered that the receptor tyrosine phosphatase DEP-1 plays a significant role in angiogenesis and that modulation of the DEP-1 receptor with certain agents can affect endothelial cell growth. The research team has developed antibodies that bind to the ectodomain of a mammalian transmembrane protein known as DEP-1 (for density enhanced protein) or CD148. CD148 (also named DEP-1/PTPn) is a receptor-like protein tyrosine phosphatase that is abundantly expressed in vascular endothelial cells, hematopoietic-cell lineages, duct epithelia of thyroid, mammary and gastrointestinal tissues.
FEATURED TECHNOLOGY

On Chip Polarimetry for HTS

Using microfluidic technology developed by the Bornhop Lab at Vanderbilt, this invention enables the rapid determination of the optical activity of compounds and solutions. Due to the nature of this invention, it is possible to screen a multitude of samples in a high throughput manner in less time with less material and greater accuracy than the industry standards.
FEATURED TECHNOLOGY

A Method for Regulating Glucokinase by Reaction With Nitric Oxide

Vanderbilt researchers have discovered a novel mechanism through which the insulin regulating enzyme glucokinase is regulated. This discovery provides a powerful way to screen for activators of glucokinase, which may lead to therapies for diabetes.
FEATURED TECHNOLOGY

Inhibition of Hyperacute Rejection in Pulmonary Xenograft

One of the several problems with organ transplantation is the actual procurement of needed organs. The number of patients requiring transplants far exceeds the number of available organs. Thus, tissues and organs from different species (xenografts) may offer help to many more potential organ donors, and consequently may help the organ shortage. However, many obstacles still remain with xenografts, with the major challenge being tissue/organ rejection. The need to reduce this rejection and the injury it can inflict upon the transplanted tissue/organ therefore remains high. Vanderbilt researchers have patented a technology that helps to prevent the rejection of transplanted tissues/organs and the injury that occurs to these tissues. This technology inhibits specific pathways that regulate platelet adhesion and aggregation, which have been linked to the rejection of transplanted tissues/organs.
FEATURED TECHNOLOGY

In Vivo Protection by Nuclear Import Inhibitor in a Mouse Model of Type 1 Diabetes (cSN-50)

Researchers at Vanderbilt have developed a peptide therapeutic that rendered non-obese diabetic (NOD) mice diabetes-free and insulin-independent for at least one year after only 2 days of treatment at the early stage of disease.
FEATURED TECHNOLOGY

Human Choline Transporter cDNA

Vanderbilt researchers report the isolation and characterization of a human cDNA encoding the high affinity, hemicholinium-3 sensitive choline transporter. This transporter is expressed in cholinergic terminals, and it provides for transport into cholinergic terminals of choline, the precursor for acetylcholine biosynthesis. The cDNA, through HC-3 radio ligand binding assays or choline transport assays, allows for high-throughput screening of choline transporter directed agents or as a negative screen to insure specificity for nicotinic and muscarinic acetylcholine receptor-directed agents (as well as other pharmaceutics). The choline transporter in vivo is highly regulated, and the human choline transporter's regulation is poorly understood. Use of the cDNA may allow for the development of novel cholinergic therapeutics targeted at choline transporter modulation. Antibodies directed against the human choline transporter should be useful probes of human cholinergic neurons. Sequences in the human choline transporter cDNA should allow for the generation of transporter specific gene probes that can be queried by in situ hybridization, PCR analyses of transporter gene expression or gene chip approaches evaluating alterations in presynaptic cholinergic function.
FEATURED TECHNOLOGY

Assay for Dopamine Neuron Viability Using C. Elegans

The loss of DA neurons is a major feature of Parkinson's disease and other neuro-generative disorders. Vanderbilt researchers have established an in vivo screen for DA neuron protective agents and genes using the nematode C. elegans. Using green fluorescent protein (GFP) expression in C. elegans DA neurons, researchers have established that the nematode is sensitive to the mammalian neurotoxins that target DA neurons in mammalian models, consistent with an environmentally triggered loss of DA neurons. They also demonstrate that agents that block the nematode DA transporter or genetic ablation of the DA transporters protect these DA neurons. Thus, researchers have established lines and conditions that can allow for the facile screening, in a high throughput format, for agents or genes that may protect DA neurons from exogenous or endogenous neurotoxin-induced cell death. The system should also be useful for identifying novel pathway controlling presynaptic DA neuron function with potential applications to Schizophrenia, ADHD and addiction, where altered DA signaling has been proposed.
FEATURED TECHNOLOGY

Highly Accurate Radio Chip Localization Technology

Summary: This technology, developed at Vanderbilt University's Institute for Software Integrated Systems, uses radio interferometry to locate tangible objects and attains, simultaneously, a higher degree of accuracy (within 3 centimeters), considerably longer range (up to 160 meters) and lower cost than other technologies.
FEATURED TECHNOLOGY

Stable HERG Expressing Cells

Vanderbilt researchers have designed a cell line with stable expression of the human heart potassium channel, HERG. This cell line has robust and very consistent cell-to-cell HERG activity without detectable endogenous ionic currents, making it ideal to use in preclinical drug screening.
FEATURED TECHNOLOGY

Treatment & Prevention of Oxidative Injury

During open heart surgery and organ transplant, surgeons have to disrupt the blood supply to the organ. Recent studies suggest that free radical production and oxidative stress can occur when the blood supply is returned to the organ, causing complications and tissue damage. Vanderbilt researchers have identified a treatment for oxidative injury that can be administered during surgery to prevent organ damage.
FEATURED TECHNOLOGY

Novel PLD Inhibitors

Vanderbilt researchers have created the first isoform-selective phospholipase D (PLD) inhibitors. These highly potent inhibitors can significantly reduce PLD activity, creating a new class of anti-metastatic agents.
FEATURED TECHNOLOGY

Sterile Blood Culture Collection Kit

Scientists at Vanderbilt have developed a sterile kit to collect blood cultures that results in substantially fewer contaminated cultures compared to the current standard of care for collecting culture specimens.

Featured Video

2012 Highlights

A motion graphic video describing operational improvements and successes of FY2012. Click here for a full PDF report.